Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor

Table 3

ADMET screening of the targeted nicotinamide derivative.

Comp.	BBB	LAS	LIA	CYP2D6	LPPB (%)
The nicotinamide compound; sorafenib	Very low	Good; Low	Good	No inhibition	>90